New corporate investors Medtronic and Itochu join existing investors St Jude Medical, Adams Street Partners, The Carlyle Group, Essex Woodlands, Kaiser Permanente Ventures, Spring Ridge Ventures and others. The company’s current round of financing will remain open for a period of time to additional investors.
Andrew Thompson, CEO of Proteus Biomedical, said: “I am pleased that we have attracted investors who endorse our vision of intelligent medicine and recognize the company’s potential to drive significant value across a number of therapeutic areas. We have established a strong foundation with our strategic partners, and look to the next phase of expansion into new areas as the first Proteus-enabled products are commercialized.”